Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.~* Men and post-menopausal women above 18 years of age.~* Reversible airway obstruction in response to classical beta2-agonist (salbutamol)~* Non/ex-smokers~Exclusion Criteria:~* Any clinically significant disease or disorder other than asthma~* Any clinically relevant abnormal findings at screening examinations~* Treatment with systemic glucocorticosteroids within the past 30 days~* Inhaled corticosteroid use if dosing is not kept constant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- crossover dose 1 (Type: EXPERIMENTAL): AZD3199 120 microgram
- crossover dose 2 (Type: EXPERIMENTAL): AZD3199 480 microgram
- crossover dose 3 (Type: EXPERIMENTAL): AZD3199 1920 microgram
- crossover dose 4 (Type: PLACEBO_COMPARATOR): Placebo
- crossover dose 5 (Type: ACTIVE_COMPARATOR): Formoterol 9 microgram
- crossover dose 6 (Type: ACTIVE_COMPARATOR): Formoterol 36 microgram

Based on this trial design, predict the completion outcome and termination type (if applicable).